It's no secret: FDA review managers would like to make "complete response" letters public. We've heard that directly from ...

We are always on the lookout for leading indicators, no matter how faint the signal. If you tend an herb garden on your back porch, you mig...

ASCO approaches, and the season of cancer vaccine hype is upon us. Exhibit A: Cleveland Clinic Researchers Develop Prototype Vaccine To Prev...

The most important single event for FDA’s drug review in 2010 and possibly beyond is coming this summer: the advisory committee re-review of...

Twenty-seven up, 27 down. Roy Halladay's perfect game on Saturday against the Marlins is an oasis in a desert of slump for the Phillies,...

It was a week of painful navel-gazing from many in the venture community, as some of the industry’s best and brightest gathered in Napa for ...

Toyota. Massey Energy. British Petroleum. Johnson & Johnson? That is not a list J&J wants to see. But, as the company testifies toda...

There is always a self-congratulatory flavor to BIO’s annual meeting. Which is as it should be: it’s the lobbying group’s best venue for jus...

The biotech M&A storm is coming. Really. So sayeth the good attorneys at the UK patent firm Marks & Clerk, based on survey data of 3...

Rumors have been circulating for weeks that Piramal, one of India's leading biopharma players, was up for sale. And just as staunchly, m...